{"id":"coronavac-vaccine","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Injection site pain or swelling"},{"rate":"10-30","effect":"Fatigue"},{"rate":"10-25","effect":"Myalgia"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains chemically inactivated whole SARS-CoV-2 virions, which cannot cause infection but retain antigenic epitopes. Upon administration, these viral antigens are presented to the immune system, triggering both humoral (antibody) and cell-mediated immune responses. This prepares the body to recognize and neutralize live virus upon exposure.","oneSentence":"CoronaVac is an inactivated SARS-CoV-2 vaccine that stimulates the immune system to produce antibodies and cellular immunity against the virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:39.873Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 in adults and adolescents"}]},"trialDetails":[{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT05904054","phase":"PHASE2","title":"Immunogenicity and Safety Study of SARS-CoV-2 DNA Vaccine (ICCOV)","status":"COMPLETED","sponsor":"Immuno Cure 3 Limited","startDate":"2023-06-15","conditions":"COVID-19","enrollment":31},{"nctId":"NCT05303584","phase":"PHASE4","title":"Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2022-04-23","conditions":"COVID-19","enrollment":362},{"nctId":"NCT05599555","phase":"","title":"Community-based Sero-epidemiological Study of COVID-19","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2022-04-28","conditions":"COVID-19","enrollment":9600},{"nctId":"NCT05697705","phase":"","title":"Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-22","conditions":"COVID-19","enrollment":188814085},{"nctId":"NCT05501522","phase":"PHASE3","title":"Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2022-12-09","conditions":"COVID-19","enrollment":840},{"nctId":"NCT06597370","phase":"","title":"Immunogenicity Induced by COVID-19 Vaccines in Mexican Population","status":"COMPLETED","sponsor":"National Polytechnic Institute, Mexico","startDate":"2021-09-01","conditions":"COVID-19 Vaccine","enrollment":80},{"nctId":"NCT04611243","phase":"","title":"Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2020-05-22","conditions":"Lung Function, Exercise Capacity, Quality of Life","enrollment":700},{"nctId":"NCT05381350","phase":"PHASE3","title":"Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-06-01","conditions":"COVID-19","enrollment":1750},{"nctId":"NCT05230940","phase":"PHASE2","title":"Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2022-02-18","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":1},{"nctId":"NCT04582344","phase":"PHASE3","title":"Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2020-09-14","conditions":"COVID-19","enrollment":10214},{"nctId":"NCT05863429","phase":"","title":"Observational National Vaccine Study","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2022-05-18","conditions":"COVID-19 Infection","enrollment":200},{"nctId":"NCT04754698","phase":"PHASE4","title":"COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2021-02-09","conditions":"Rheumatic Disease, HIV Infections, AIDS","enrollment":2196},{"nctId":"NCT05897190","phase":"PHASE1","title":"Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster","status":"COMPLETED","sponsor":"Argorna Pharmaceuticals Co., LTD","startDate":"2022-05-16","conditions":"SARS-CoV-2","enrollment":60},{"nctId":"NCT05387317","phase":"PHASE3","title":"Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)","status":"WITHDRAWN","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-04","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04942405","phase":"PHASE3","title":"Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-06-21","conditions":"Covid19","enrollment":1290},{"nctId":"NCT05077176","phase":"PHASE3","title":"Phase 3 Booster Vaccination Against COVID-19","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-10-08","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":4340},{"nctId":"NCT05104385","phase":"","title":"Hacettepe University COVID-19 Vaccinated's Health Cohort- Students of Health Sciences","status":"COMPLETED","sponsor":"Hacettepe University","startDate":"2021-06-21","conditions":"COVID-19 Pandemic, SARS-CoV2 Infection, Immunization; Infection","enrollment":1223},{"nctId":"NCT04898946","phase":"","title":"Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong","status":"COMPLETED","sponsor":"Hong Kong Sanatorium & Hospital","startDate":"2021-03-07","conditions":"Covid-19 Vaccine","enrollment":480},{"nctId":"NCT04456595","phase":"PHASE3","title":"Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2020-07-21","conditions":"COVID-19","enrollment":12688},{"nctId":"NCT04747821","phase":"PHASE4","title":"An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-02-07","conditions":"Covid19","enrollment":27711},{"nctId":"NCT05593042","phase":"PHASE2","title":"Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-11-28","conditions":"COVID-19, Vaccines","enrollment":551},{"nctId":"NCT04832932","phase":"","title":"The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes","status":"UNKNOWN","sponsor":"Mebo Research, Inc.","startDate":"2021-01-05","conditions":"COVID-19 Vaccines","enrollment":2000},{"nctId":"NCT04800133","phase":"PHASE2","title":"Covid-19 Vaccination in Adolescents and Children","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-05-08","conditions":"Covid19","enrollment":1018},{"nctId":"NCT05057169","phase":"PHASE4","title":"Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-11-18","conditions":"COVID-19 Vaccination","enrollment":400},{"nctId":"NCT04979949","phase":"PHASE2","title":"Booster Vaccination Against COVID-19","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2021-07-12","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":222},{"nctId":"NCT05052307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2021-11-03","conditions":"Covid19","enrollment":4574},{"nctId":"NCT05112913","phase":"PHASE4","title":"Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-07-27","conditions":"COVID-19","enrollment":2520},{"nctId":"NCT05329038","phase":"PHASE4","title":"Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2022-04-19","conditions":"COVID-19","enrollment":180},{"nctId":"NCT05403307","phase":"","title":"A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil","status":"COMPLETED","sponsor":"Hospital Moinhos de Vento","startDate":"2022-06-08","conditions":"COVID-19","enrollment":757},{"nctId":"NCT05137418","phase":"PHASE3","title":"Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 Years","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-11-27","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT04992260","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-09-10","conditions":"COVID-19","enrollment":11349},{"nctId":"NCT05788185","phase":"PHASE1, PHASE2","title":"Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Individuals","status":"TERMINATED","sponsor":"RVAC Medicines (US), Inc.","startDate":"2023-03-22","conditions":"Infectious Disease, COVID-19","enrollment":24},{"nctId":"NCT04775069","phase":"PHASE4","title":"Antibody Response to COVID-19 Vaccines in Liver Disease Patients","status":"COMPLETED","sponsor":"Humanity & Health Medical Group Limited","startDate":"2021-05-21","conditions":"Chronic Liver Disease","enrollment":232},{"nctId":"NCT04911790","phase":"PHASE4","title":"Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-06-05","conditions":"COVID-19","enrollment":131650},{"nctId":"NCT05198336","phase":"PHASE4","title":"Immunogenicity of an Inactivated COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-01-08","conditions":"COVID-19","enrollment":395},{"nctId":"NCT04992208","phase":"PHASE4","title":"Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-07-24","conditions":"COVID-19","enrollment":31041},{"nctId":"NCT05254236","phase":"PHASE2","title":"Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong","status":"WITHDRAWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-02-10","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05411471","phase":"PHASE2","title":"Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain","status":"COMPLETED","sponsor":"Sinovac Biotech (Hong Kong) Limited","startDate":"2022-06-08","conditions":"COVID-19","enrollment":221},{"nctId":"NCT04884685","phase":"PHASE2","title":"Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-05-03","conditions":"COVID-19","enrollment":500},{"nctId":"NCT05205096","phase":"PHASE1, PHASE2","title":"Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-11-10","conditions":"COVID-19","enrollment":480},{"nctId":"NCT05188677","phase":"PHASE3","title":"Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2022-06-13","conditions":"COVID-19","enrollment":1831},{"nctId":"NCT04993209","phase":"PHASE1","title":"Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-07-09","conditions":"Coronavirus Infections, Healthy","enrollment":320},{"nctId":"NCT05710289","phase":"","title":"A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.","status":"WITHDRAWN","sponsor":"SK Bioscience Co., Ltd.","startDate":"2023-02","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05928455","phase":"EARLY_PHASE1","title":"The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001","status":"UNKNOWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-05-14","conditions":"COVID-19, Vaccine Reaction","enrollment":120},{"nctId":"NCT05918939","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-09-05","conditions":"COVID-19 Pandemic, COVID-19 Vaccines","enrollment":350},{"nctId":"NCT05226429","phase":"PHASE1, PHASE2","title":"UNAIR Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-02-08","conditions":"COVID-19 Pandemic, Vaccine Reaction","enrollment":495},{"nctId":"NCT05169008","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents","status":"TERMINATED","sponsor":"CanSino Biologics Inc.","startDate":"2022-02-25","conditions":"COVID-19","enrollment":91},{"nctId":"NCT05096832","phase":"PHASE3","title":"Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2021-11-03","conditions":"COVID-19 Pandemic","enrollment":10381},{"nctId":"NCT05228912","phase":"","title":"Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.","status":"COMPLETED","sponsor":"Hospital Clinica Nova","startDate":"2021-02-26","conditions":"Vaccine Adverse Reaction, COVID-19, Vaccine Reaction","enrollment":1870},{"nctId":"NCT05156632","phase":"PHASE3","title":"Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above","status":"WITHDRAWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2023-02-20","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05428592","phase":"PHASE3","title":"Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-04","conditions":"SARS-CoV-2","enrollment":1100},{"nctId":"NCT04651790","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2020-11-27","conditions":"Covid19, Vaccines","enrollment":2300},{"nctId":"NCT05683561","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2023-01-25","conditions":"COVID-19 SARS-CoV-2 Infection","enrollment":6000},{"nctId":"NCT05367895","phase":"","title":"Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-07-30","conditions":"COVID-19","enrollment":14000},{"nctId":"NCT05433272","phase":"PHASE3","title":"Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated","status":"UNKNOWN","sponsor":"Sinovac Biotech (Colombia) S.A.S.","startDate":"2023-08-10","conditions":"COVID-19","enrollment":1400},{"nctId":"NCT05668065","phase":"PHASE3","title":"Immunogenicity of Heterologous Versus Homologous Prime Boost Schedule With mRNA and Inactivated COVID-19 Vaccines","status":"COMPLETED","sponsor":"Institut Pasteur de Tunis","startDate":"2021-11-22","conditions":"COVID-19","enrollment":199},{"nctId":"NCT05583357","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351","status":"UNKNOWN","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2022-08-15","conditions":"COVID-19 Pandemic","enrollment":40},{"nctId":"NCT05508477","phase":"PHASE3","title":"UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-06-28","conditions":"COVID-19 Pandemic, COVID-19 Vaccines","enrollment":4005},{"nctId":"NCT04974164","phase":"","title":"Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-08-17","conditions":"COVID-19","enrollment":1400},{"nctId":"NCT04952727","phase":"PHASE4","title":"Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-08-26","conditions":"COVID-19","enrollment":300},{"nctId":"NCT05148949","phase":"PHASE4","title":"Study on Three Doses of an Inactivated COVID-19 Vaccine in Chinese Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-12-22","conditions":"COVID-19, Pulmonary Tuberculosis","enrollment":240},{"nctId":"NCT05165966","phase":"PHASE4","title":"Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-10-20","conditions":"COVID-19","enrollment":340},{"nctId":"NCT05398926","phase":"PHASE4","title":"Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-12-06","conditions":"COVID-19","enrollment":400},{"nctId":"NCT05150496","phase":"PHASE2","title":"Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey","status":"SUSPENDED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-12-15","conditions":"COVID-19","enrollment":640},{"nctId":"NCT05165732","phase":"PHASE4","title":"Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19","status":"SUSPENDED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-12-20","conditions":"COVID-19","enrollment":480},{"nctId":"NCT05216484","phase":"PHASE3","title":"Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (6 Months After Two Doses)","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2022-02-18","conditions":"SARS-CoV-2 Infection","enrollment":480},{"nctId":"NCT05029245","phase":"PHASE3","title":"IntraDermal Versus Intramuscular Comirnaty® Efficacy Study","status":"WITHDRAWN","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2021-08-31","conditions":"Covid19 Vaccine, Covid19","enrollment":""},{"nctId":"NCT05289206","phase":"NA","title":"Immune Response of an Interchangeable Booster Vaccine Against COVID-19 Among Individuals With Risk Factors for Severity","status":"UNKNOWN","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2021-09-30","conditions":"Comorbidities and Coexisting Conditions, Healthy","enrollment":4446},{"nctId":"NCT05313074","phase":"NA","title":"SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients","status":"COMPLETED","sponsor":"National Cancer Institute, Thailand","startDate":"2021-03-23","conditions":"COVID-19, Cancer","enrollment":311},{"nctId":"NCT04953325","phase":"PHASE4","title":"Immunogenicity and Safety of an Inactivated COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-07-09","conditions":"COVID-19","enrollment":270},{"nctId":"NCT04894227","phase":"PHASE4","title":"Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-05-11","conditions":"COVID-19","enrollment":1080},{"nctId":"NCT04834869","phase":"","title":"COVID-19 Vaccines Safety Tracking (CoVaST)","status":"RECRUITING","sponsor":"Masaryk University","startDate":"2021-04-01","conditions":"Adverse Reaction to Vaccine, COVID19 Vaccine","enrollment":30000},{"nctId":"NCT04892459","phase":"PHASE4","title":"Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-05-25","conditions":"COVID-19","enrollment":300},{"nctId":"NCT04801667","phase":"PHASE4","title":"Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"Hospital do Rim e Hipertensão","startDate":"2021-03-20","conditions":"SARS-CoV Infection, Coronavirus Infection, Vaccine Adverse Reaction","enrollment":3371},{"nctId":"NCT05079217","phase":"PHASE4","title":"Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-12-17","conditions":"COVID-19","enrollment":1200},{"nctId":"NCT05163652","phase":"PHASE3","title":"Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on Different COVID-19 Inactivated Vaccine in Adults Aged 18 Years and Above","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-12-18","conditions":"SARS-CoV-2 Infection","enrollment":432},{"nctId":"NCT05225285","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents","status":"UNKNOWN","sponsor":"Federal University of Espirito Santo","startDate":"2022-01-21","conditions":"COVID-19","enrollment":1120},{"nctId":"NCT05119738","phase":"","title":"Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2021-10-27","conditions":"Sars-CoV-2 Infection","enrollment":122},{"nctId":"NCT05124509","phase":"","title":"Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2021-10-06","conditions":"COVID-19, SARS-CoV-2 Infection, Solid Organ Transplant","enrollment":147},{"nctId":"NCT05087368","phase":"PHASE2","title":"Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2021-12-01","conditions":"Covid19","enrollment":520},{"nctId":"NCT04962308","phase":"PHASE4","title":"Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults","status":"UNKNOWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2021-06-19","conditions":"COVID-19","enrollment":1400},{"nctId":"NCT05026879","phase":"","title":"Adverse Events Report of Inactivated COVID-19 Vaccine","status":"COMPLETED","sponsor":"Bozyaka Training and Research Hospital","startDate":"2021-02-14","conditions":"COVID-19, Vaccine Adverse Reaction","enrollment":4040},{"nctId":"NCT04992182","phase":"PHASE2","title":"Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster","status":"UNKNOWN","sponsor":"Universidad del Desarrollo","startDate":"2021-07-08","conditions":"Covid19","enrollment":534},{"nctId":"NCT04789356","phase":"PHASE4","title":"Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity","status":"UNKNOWN","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2021-03-18","conditions":"Covid19","enrollment":6233},{"nctId":"NCT04756830","phase":"PHASE4","title":"A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2021-02-19","conditions":"COVID-19","enrollment":1200},{"nctId":"NCT04765215","phase":"","title":"Investigation of the Effectiveness of CoronaVac Vaccine in Cancer Patients With Active Chemotherapy and Comparison With Healthy People.","status":"UNKNOWN","sponsor":"Asoc. Prof. Erdoğan Selçuk Şeber","startDate":"2021-03-31","conditions":"Is the Coronovac Vaccine Effective in Patients Receiving Chemotherapy","enrollment":291},{"nctId":"NCT04854408","phase":"","title":"Evaluation of the Effect of Coronavac Vaccine (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 Vaccine) on Healthcare Workers' Menstrual Patterns","status":"COMPLETED","sponsor":"Kanuni Sultan Suleyman Training and Research Hospital","startDate":"2021-03-18","conditions":"Covid19, Vaccine Reaction, Coronavirus","enrollment":300},{"nctId":"NCT04751721","phase":"NA","title":"Oxidative Stress Parameters, Trace Element and Quality of Life in Women Before and After Covid-19 Vaccines","status":"UNKNOWN","sponsor":"Izmir Bakircay University","startDate":"2021-02","conditions":"Covid-19 Vaccine","enrollment":20},{"nctId":"NCT04751695","phase":"NA","title":"Oxidative Stress Parameters, Trace Element and Quality of Life in Men Before and After Covid-19 Vaccines","status":"UNKNOWN","sponsor":"Izmir Bakircay University","startDate":"2021-02","conditions":"Covid-19 Vaccine","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":233,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sinovac"],"phase":"phase_3","status":"active","brandName":"CoronaVac Vaccine","genericName":"CoronaVac Vaccine","companyName":"Clover Biopharmaceuticals AUS Pty","companyId":"clover-biopharmaceuticals-aus-pty","modality":"Biologic","firstApprovalDate":"","aiSummary":"CoronaVac is an inactivated SARS-CoV-2 vaccine that stimulates the immune system to produce antibodies and cellular immunity against the virus. Used for Prevention of COVID-19 in adults and adolescents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}